Corporate Website
Africa
Argentina
Asia
Australia
Belgium
Brazil
Bulgaria
Canada (EN)
Chile
China
Colombia
Denmark
Egypt
France
Germany
Greece
Hungary
Indonesia
Italia
India
Japan
Korea
Malaysia
Mexico
Middle East
Netherlands
Peru
Philippines
Poland
Portugal
Romania
Russia
South Africa
Spain
Sweden
Thailand
Tunisia
Turkey
Ukraine
United Kingdom
USA
Vietnam
Your search for "news" return 98 results.
Ceva posts strong double-digit growth again in first half of 2015 >
Consolidated sales of the Ceva Group reached €424m at the end of June 2015, representing growth of 16% and +12% at constant perimeter and exchange rates.
Ceva Biomune Celebrates Completion of $10MM Expansion in Lenexa >
Ceva Biomune has again expanded facilities to meet demand for its vaccine products.
Van Buskirk to serve as Director, Ceva Business Solutions >
Ceva Animal Health has promoted Mark Van Buskirk to the role of Director, Ceva Business Solutions.
Dermatology >
The skin of dogs and cats is their first line of defense against environmental aggressors.
Cardiology >
Congestive Heart Failure In Dogs Just Got Easier To Treat.
Ceva Animal Health posts strong double-digit growth again in 2014 >
Sales grew in all zones and across all species
Ceva Introduces Feliway® MultiCat pheromone to reduce tension and conflict in multi-cat households >
Ceva Animal Health has introduced Feliway MultiCat® a feline appeasing pheromone clinically proven to reduce social tension and conflict between cats living in the same home.
Ceva receives US patent for innovative delivery system of treating poultry hatchlings through gel application >
Poultry producers now have access to a new method for administering vaccines, probiotics and nutritional supplements in the hatchery through a soft edible gel.
Cigainero joins Ceva Animal Health >
Travis Cigainero, DVM has joined Ceva Animal Health as Manager of Broiler Technical Services
Ceva Biomune is again expanding facilities to meet demand for its vaccine products. >
Ceva Biomune is again expanding facilities to meet demand for its vaccine products.